Advances in radiation oncology · 2026
Comparable Outcomes Without Routine Pan-mucosal Irradiation in Head and Neck Carcinoma of Unknown Primary.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Allaf Mahmoud, Diederich Linda, Buchali André, Olze Heidi, Stromberger Carmen, Franzen Achim, Coordes Annekatrin
Аннотация
PURPOSE: Evaluate whether adding pan-mucosal irradiation (50 Gy) reduces recurrence or improves survival in head and neck carcinoma of unknown primary.
METHODS AND MATERIALS: Retrospective 2-center analysis (center 1, 2009-2018, and center 2, 2005-2023). All patients underwent neck dissection with adjuvant irradiation to lymphatic drainage or definitive radiochemotherapy; center 2 additionally received 50 Gy pan-mucosal irradiation to the upper aerodigestive tract. Definitive radiation therapy/chemoradiation therapy was used for advanced nodal disease.
RESULTS: Of 164 screened, 134 were included (center 1, n = 88, and center 2, n = 46). Median follow-up was 72 months (95% CI, 48-96). Sixty-five patients (42%) died (37 vs 28). Overall survival did not differ between centers (log-rank P = .899). Combining centers 1 and 2, there were 39 recurrences in 134 patients; 24 out of 88 patients (27.3%) in center 1 and 15 out of 46 patients in center 2 (32.6%), P = .519. There were no differences noted in time-to-event analysis (log-rank P = .724). Mucosal recurrences occurred in 13 patients (9 vs 4; P = .282); all arose more than 36 months after diagnosis and exclusively in persistent smokers.
CONCLUSION: In thoroughly staged head and neck carcinoma of unknown primary, adding pan-mucosal irradiation to standard nodal irradiation was not associated with improved survival or lower mucosal recurrence rates compared with nodal-only fields. The late occurrence of mucosal events and their association with persistent smoking suggest second primary tumors rather than missed index lesions. Given potential toxicity and quality-of-life trade-offs, routine pan-mucosal irradiation may not be warranted, and treatment should be individualized.
METHODS AND MATERIALS: Retrospective 2-center analysis (center 1, 2009-2018, and center 2, 2005-2023). All patients underwent neck dissection with adjuvant irradiation to lymphatic drainage or definitive radiochemotherapy; center 2 additionally received 50 Gy pan-mucosal irradiation to the upper aerodigestive tract. Definitive radiation therapy/chemoradiation therapy was used for advanced nodal disease.
RESULTS: Of 164 screened, 134 were included (center 1, n = 88, and center 2, n = 46). Median follow-up was 72 months (95% CI, 48-96). Sixty-five patients (42%) died (37 vs 28). Overall survival did not differ between centers (log-rank P = .899). Combining centers 1 and 2, there were 39 recurrences in 134 patients; 24 out of 88 patients (27.3%) in center 1 and 15 out of 46 patients in center 2 (32.6%), P = .519. There were no differences noted in time-to-event analysis (log-rank P = .724). Mucosal recurrences occurred in 13 patients (9 vs 4; P = .282); all arose more than 36 months after diagnosis and exclusively in persistent smokers.
CONCLUSION: In thoroughly staged head and neck carcinoma of unknown primary, adding pan-mucosal irradiation to standard nodal irradiation was not associated with improved survival or lower mucosal recurrence rates compared with nodal-only fields. The late occurrence of mucosal events and their association with persistent smoking suggest second primary tumors rather than missed index lesions. Given potential toxicity and quality-of-life trade-offs, routine pan-mucosal irradiation may not be warranted, and treatment should be individualized.